# Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

> **NCT03320330** · PHASE1,PHASE2 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 26 (actual)

## Conditions studied

- Recurrent Malignant Solid Neoplasm
- Recurrent Osteosarcoma
- Refractory Malignant Solid Neoplasm
- Refractory Osteosarcoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pepinemab
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT03320330
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-31
- **Primary completion:** 2020-12-31
- **Final completion:** 2024-06-30
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03320330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03320330, "Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03320330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*